Takara Bio Completes Acquisition of Rubicon
Takara Bio has announced that it has completed the acquisition of Rubicon Genomics,
Under the merger agreement executed with Rubicon, TBUSH paid 75 million US dollars to acquire 100% of the equity in Rubicon. TBUSH is a wholly owned subsidiary of Takara Bio Inc. (“Takara Bio”), a leading global biotechnology and life science company headquartered in Shiga, Japan. Takara Bio USA, Inc. (“TBUSA”, formerly known as Clontech Laboratories, Inc.) is a wholly owned subsidiary of TBUSH, and both TBUSA and TBUSH are part of the global Takara Bio Group. The impact of the acquisition on Takara Bio Inc.’s financial results in 2017 will be immaterial.
The Takara Bio Group provides a wide range of life science products and services under the Takara®, Clontech®, and Cellartis® brands that assist discovery, translational, and clinical scientists in the advancement of their work. The Rubicon acquisition will allow the Takara Bio Group to augment and expand its worldwide commercial offerings in next generation sequencing (NGS) sample preparation and expand into new markets.
“We are pleased to announce the completion of this transaction and officially welcome Rubicon to the Takara Bio Group,” said Carol Lou, President, TBUSA. “We are excited about the synergy between Rubicon’s technologies and products and our own longstanding expertise and SMART®-based portfolio of cDNA synthesis, low-input, and single cell RNA-seq products. We now have an expanded NGS and genetic analysis capabilities that strengthen our product portfolio and allow us to better serve the life science research market, as well as creating new opportunities for us to serve customers in IVF and other clinical markets. We are excited to move forward as one organization positioned for growth.”
As previously communicated, Rubicon’s technology is also complementary with the WaferGen Bio-systems, Inc. instrument platforms and technologies. TBUSH announced plans to acquire WaferGen in 2016, and anticipates that the merger will close in March 2017. The combined acquisitions are synergistic and will allow the Takara Bio Group to provide the exciting benefits of the combined portfolios to the life science community.
Scientists used a gene editing method called CRISPR/Cas9 to generate mice that faithfully mimic a fatal respiratory disorder in newborn infants that turns their lips and skin blue. The new laboratory model allowed researchers to pinpoint the ailment's cause and develop a potential and desperately needed nanoparticle-based treatment.READ MORE